Literature DB >> 21890811

Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression.

Meike de Wit1, Connie R Jimenez, Beatriz Carvalho, Jeroen A M Belien, Pien M Delis-van Diemen, Sandra Mongera, Sander R Piersma, Maindad Vikas, Sanjay Navani, Fredrik Pontén, Gerrit A Meijer, Remond J A Fijneman.   

Abstract

BACKGROUND AND
OBJECTIVE: Early detection of colon adenomas at high risk of progression and early-stage colorectal cancer (CRC) is an effective approach to reduce CRC death rates. Current screening methods lack specificity as they detect many adenomas that will never progress to CRC. The authors aimed to identify cell surface protein biomarkers with extracellular domains that could be targeted for molecular imaging and discriminate low-risk adenomas and normal colon from high-risk adenomas and CRC.
DESIGN: Cell surface proteins of five CRC cell lines were biotinylated, isolated and analysed by in-depth proteomics using gel electrophoresis and nanoliquid chromatography coupled to tandem mass spectrometry. Differential expression in adenomas and CRCs was based on mRNA expression and verified by immunohistochemical staining of tissue microarrays.
RESULTS: In total, 2609 proteins were identified in the cell surface fractions. Of these, 44 proteins were selected as promising cell surface candidate biomarkers for adenoma-to-carcinoma progression based on the following criteria: protein identification in at least four out of five cell lines, a predicted (trans)membrane location and increased mRNA expression in CRCs compared to adenomas. Increased protein expression in high-risk adenomas and CRCs compared to low-risk adenomas was confirmed by immunohistochemistry for glucose transporter type 1 (gene symbol SLC2A1; p<0.00001) and prion protein (gene symbol PRNP; p<0.005).
CONCLUSION: This study revealed glucose transporter type 1, prion protein and 42 other cell surface candidate biomarkers for adenoma-to-carcinoma progression that could potentially serve as targets for emerging molecular imaging modalities like optical imaging, ¹⁹F-MRI and positron emission tomography.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21890811     DOI: 10.1136/gutjnl-2011-300511

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  27 in total

1.  A Raman-based endoscopic strategy for multiplexed molecular imaging.

Authors:  Cristina L Zavaleta; Ellis Garai; Jonathan T C Liu; Steven Sensarn; Michael J Mandella; Dominique Van de Sompel; Shai Friedland; Jacques Van Dam; Christopher H Contag; Sanjiv S Gambhir
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-23       Impact factor: 11.205

2.  Role of HSPA1L as a cellular prion protein stabilizer in tumor progression via HIF-1α/GP78 axis.

Authors:  J H Lee; Y-S Han; Y M Yoon; C W Yun; S P Yun; S M Kim; H Y Kwon; D Jeong; M J Baek; H J Lee; S-J Lee; H J Han; S H Lee
Journal:  Oncogene       Date:  2017-07-31       Impact factor: 9.867

Review 3.  Implications of peptide assemblies in amyloid diseases.

Authors:  Pu Chun Ke; Marc-Antonie Sani; Feng Ding; Aleksandr Kakinen; Ibrahim Javed; Frances Separovic; Thomas P Davis; Raffaele Mezzenga
Journal:  Chem Soc Rev       Date:  2017-10-30       Impact factor: 54.564

4.  CSE1L, DIDO1 and RBM39 in colorectal adenoma to carcinoma progression.

Authors:  Anke H Sillars-Hardebol; Beatriz Carvalho; Jeroen A M Beliën; Meike de Wit; Pien M Delis-van Diemen; Marianne Tijssen; Mark A van de Wiel; Fredrik Pontén; Gerrit A Meijer; Remond J A Fijneman
Journal:  Cell Oncol (Dordr)       Date:  2012-06-19       Impact factor: 6.730

Review 5.  Targeting prion protein interactions in cancer.

Authors:  Tiago G Santos; Marilene H Lopes; Vilma R Martins
Journal:  Prion       Date:  2015       Impact factor: 3.931

6.  YAP1 and PRDM14 converge to promote cell survival and tumorigenesis.

Authors:  Miju Kim; Seav Huong Ly; Yingtian Xie; Gina N Duronio; Dane Ford-Roshon; Justin H Hwang; Rita Sulahian; Jonathan P Rennhack; Jonathan So; Ole Gjoerup; Jessica A Talamas; Maximilien Grandclaudon; Henry W Long; John G Doench; Nilay S Sethi; Marios Giannakis; William C Hahn
Journal:  Dev Cell       Date:  2022-01-05       Impact factor: 12.270

7.  Targeting prion-like protein doppel selectively suppresses tumor angiogenesis.

Authors:  Taslim A Al-Hilal; Seung Woo Chung; Jeong Uk Choi; Farzana Alam; Jooho Park; Seong Who Kim; Sang Yoon Kim; Fakhrul Ahsan; In-San Kim; Youngro Byun
Journal:  J Clin Invest       Date:  2016-03-07       Impact factor: 14.808

Review 8.  Gene expression resulting from PrPC ablation and PrPC overexpression in murine and cellular models.

Authors:  Franc Llorens; Isidre Ferrer; José Antonio del Río
Journal:  Mol Neurobiol       Date:  2013-08-16       Impact factor: 5.590

9.  The nucleo-junctional interplay of the cellular prion protein: A new partner in cancer-related signaling pathways?

Authors:  Monique Rousset; Armelle Leturque; Sophie Thenet
Journal:  Prion       Date:  2016-03-03       Impact factor: 3.931

Review 10.  Pathophysiological mechanisms of death resistance in colorectal carcinoma.

Authors:  Ching-Ying Huang; Linda Chia-Hui Yu
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.